AQST (Aquestive Therapeutics, Inc.) Stock Financials & Earnings

AQSTAquestive Therapeutics, Inc.

Mkt Cap$431M

Revenue (TTM)$45M

Net Income (TTM)-$84M

EPS (TTM)-$0.76

Free Cash Flow (TTM)-$53M

Gross Margin-35.0%

Op. Margin-159.5%

Net Margin-188.1%

FCF Margin-119.0%

P/S Ratio (TTM)9.7x

P/E Ratio (TTM)—

YoY Rev Growth-22.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$11M	$6M	-$5M
Q2 23	$13M	$7M	-$4M
Q3 23	$13M	$8M	-$2M
Q4 23	$13M	$9M	-$4M
Q1 24	$12M	$8M	-$9M
Q2 24	$20M	$16M	$55K
Q3 24	$14M	$9M	-$8M
Q4 24	$12M	$7M	-$14M
Q1 25	$9M	$5M	-$19M
Q2 25	$10M	$5M	-$11M
Q3 25	$13M	$8M	-$11M
Q4 25	$13M	-$34M	-$29M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Co-Development and Research Fees	License and Royalty Revenue	Manufacture and Supply Revenue	Manufactured Product, Other
Q1 23	$453K	$919K	$10M	—
Q2 23	$124K	$1M	$12M	—
Q3 23	$490K	$1M	$11M	—
Q4 23	$335K	$2M	$11M	—
Q1 24	$403K	$1M	$11M	—
Q2 24	$756K	$11M	$8M	—
Q3 24	$492K	$2M	$11M	$217K
Q1 25	$418K	$790K	$7M	$319K
Q3 25	$302K	$1M	$11M	—
Q4 25	$181K	$852K	$12M	—

Revenue by Geography

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$27M	$0	$27M
Q2 23	$22M	$0	$22M
Q3 23	$25M	$0	$25M
Q4 23	$24M	$0	$24M
Q1 24	$95M	$0	$95M
Q2 24	$90M	$0	$90M
Q3 24	$78M	$0	$78M
Q4 24	$72M	$0	$72M
Q1 25	$69M	$0	$69M
Q2 25	$61M	$0	$61M
Q3 25	$129M	$0	$129M
Q4 25	$121M	$0	$121M

Shares Outstanding

Revenue Per Employee

Revenue / Employee